findmyKOL
Clinical trialNCT06529822RecruitingPhase 1Interventional

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

SponsorWashington University School of MedicineEnrollment64Gastroesophageal AdenocarcinomaMelanomaMuscle-Invasive Bladder CarcinomaNon-small Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Adventhealth

    Orlando, Florida, United States

    Guru P Sonpavde, M.D.
    Not, yet, recruiting
  • Washington University School of Medicine

    St Louis, Missouri, United States

    Eric Knoche, M.D.Feng Gao, M.D., Ph.D., MPHGeorge Ansstas, M.D.Jeffrey Ward, M.D., Ph.D.Malachi Griffith, Ph.D.Melissa Reimers, M.D.Obi Griffith, Ph.D.Patrick Grierson, M.D.Peter Oppelt, M.D.Ramon Jin, M.D.Robert Schreiber, Ph.D.William Gillanders, M.D.
    Recruiting
  • Ohio State University

    Columbus, Ohio, United States

    Elshad Hasanov, M.D., Ph.D.
    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Poly ICLCSynthetic long peptide personalized cancer vaccine
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 Mar 2025
Primary completion
31 Jan 2030
Completion
30 Jun 2034
Last update posted
17 Jul 2026
Registered enrollment
64
Registry id
NCT06529822
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.